Radiation therapy for prostate cancer in the new S3 guideline. Part 1: Localized and locally advanced prostate cancer;Strahlentherapie des Prostatakarzinoms in der neuen S3-leitlinie Teil 1: Lokal begrenztes und lokal fortgeschrittenes prostatakarzinom

Urologe - Ausgabe A

Volumn 49, Issue 2, 2010, Pages 211-215

  Bohmer D ^a   Wenz, F ^b   Martin, T ^c   Sedlmayr, F ^d   Hinkelbein, W ^a   Wiegel, T ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Praxisgemeinschaft für Strahlentherapie und Radioonkologie   (Germany)

^d Salzburger Landeskliniken   (Austria)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Hormone therapy; Radiation therapy; S3 guideline prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; DIGITAL RECTAL EXAMINATION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; PRACTICE GUIDELINE; PROSTATE CANCER; RADIATION DOSE; REVIEW; RISK ASSESSMENT; S3 GUIDELINE; TREATMENT DURATION; TREATMENT INDICATION;

EID: 77952644253     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-010-2241-8     Document Type: Review

References (32)

1. Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171 (6):2122-2127 (Pubitemid 38625418)
2. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV (2009) Role of intensity-modulated radiotherapy In reducing toxicity In dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685-691
3. Bohrer M, Schröder P, Welzel G et al (2008) Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer. Strahlenther Onkol 184:674-678
4. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation In patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103-106
5. Bolla M, Reljke TM de, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516-2527
6. D'Amico A, Altschuler M, Whittington R et al (1993) The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1(4):219-222
7. D'Amico AV, Manola J, Loffredo M et al (2004) 6month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7):821-827 (Pubitemid 39079668)
8. Dearnaley DP, Khoo VS, Norman AR et al (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy In prostate cancer: a randomised trial. Lancet 353(91 49):267-272
9. Dearnaley DP, Sydes MR, Graham JD et al (2007) RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475-487
10. Denham JW, Steigler A, Lamb DS et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11 ):841-850 (Pubitemid 41614795)
11. Engelbrecht MR, Jager GJ, Lahelj RJ et al (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12(9):2294-2302 (Pubitemid 36940327)
12. Granfors T, Modig H, Damber JE, Tomic R (2006) Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176(2):544-547 (Pubitemid 43927879)
13. Hanks GE, Pajak TF, Porter A et al (2004) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy In locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21(21):3972-3978. Erratum in: J Clin Oncol 22(2):386
14. Heidenreich A, Aus G, Abbou CC et al (2007) European Association of Urology. EAU guidelines on prostate cancer. EAU, Arnhem
15. Heemsbergen WD, Peeters ST, Koper PC et al (2006) Acute and late gastrointestinal toxicity after radiotherapy In prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66(1):3-10
16. Köhler FM, Boda-Heggemann J, Küpper B et al (2009) Phantom measurements to quantify the accuracy of a commercially available Cone Beam CT gray value matching algorithm using multiple fiducials. Strahlenther Onkol 185:49-55
17. Kuban DA, Tucker SL, Dong L et al (2008) Longterm results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74 (Pubitemid 350251041)
18. Kumar S, Shelley M, Harrison C et al (2006) Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019
19. Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68(5):1424-1430
20. Lawton CA, DeSilvio M, Roach M 3rd et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646-655
21. Lohr F, Fuss M, Tiefenbacher U et al (2004) Optimierter Einsatz der Strahlentherapie durch IMRT und Präzisionslokalisationsverfahren bei der Behandlung des fortgeschrittenen Prostatakarzinoms. Urologe A 43:43-51 (Pubitemid 38209015)
22. Morris DE, Emami B, Mauch PM et al (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62(1):3-19 (Pubitemid 40591918)
23. Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990-1996 (Pubitemid 46622106)
24. Perez CA, Michalski JM, Purdy JA et al (2000) Three dimensional comformal therapy or standard irradiation In localized carcinoma of prostate: preliminary resulst of a nonrandomized comaprison. Int J Radiat Oncol Biol Phys 47(3):629-637
25. Pilepich MV, Winter K, Lawton CA et al (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61(5):1285-1290 (Pubitemid 40470408)
26. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097-1105 (Pubitemid 34787842)
27. Shipley WU, Lu JD, Pilepich MV et al (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression In prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54(5):1302-1310
28. Van Poppel H, Vekemans K, Da Pozzo L et al (2006) Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42(8):1062-1067
29. Ward JF, Slezak JM, Blute ML et al (2005) Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95(6):751-756 (Pubitemid 40547200)
30. Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG- 7/ SFUO-3): an open randomised phase III trial. Lancet 373(9660):301-308
31. Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Longterm results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028-1033
32. Zelefsky MJ, Yamada Y, Kollmeier MA et al (2008) Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 53(6):1172-1179